CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

Active, not recruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

August 1, 2024

Study Completion Date

July 31, 2025

Conditions
Heart Transplant InfectionKidney Transplant InfectionLiver Transplant InfectionCMV
Interventions
OTHER

CMV T cell Immunity Assay

Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)

Trial Locations (12)

10467

Albert Einstein College of Medicine/Children's Hospital at Montefiore, New York

15224

University of Pittsburgh Medical Center/Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

27710

Duke University Medical Center/Duke Children's Hosptial, Durham

30322

Emory University Medical Center/Children's Hospital of Atlanta, Atlanta

37232

Vanderbilt University Medical Center, Nashville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Northwestern University Medical Center/Lurie Children's Hospital of Chicago, Chicago

64108

Children's Mercy Hospital, Kansas City

68198

University of Nebraska Medical Center, Omaha

94305

Stanford University Medical Center/Lucile Packard Children's Hospital Stanford, Stanford

02115

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

ViraCor Laboratories

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER